Metabolomic Profiling to Identify Molecular Biomarkers of Cellular Response to Methotrexate In Vitro
dc.contributor.author | Funk, Ryan S. | |
dc.contributor.author | Singh, Rakesh K. | |
dc.contributor.author | Becker, Mara L. | |
dc.date.accessioned | 2020-09-17T16:06:19Z | |
dc.date.available | 2020-09-17T16:06:19Z | |
dc.date.issued | 2019-10-25 | |
dc.identifier.citation | Funk, R.S., Singh, R.K. and Becker, M.L. (2020), Metabolomic Profiling to Identify Molecular Biomarkers of Cellular Response to Methotrexate In Vitro. Clin Transl Sci, 13: 137-146. doi:10.1111/cts.12694 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/30748 | |
dc.description | A grant from the One-University Open Access Fund at the University of Kansas was used to defray the author's publication fees in this Open Access journal. The Open Access Fund, administered by librarians from the KU, KU Law, and KUMC libraries, is made possible by contributions from the offices of KU Provost, KU Vice Chancellor for Research & Graduate Studies, and KUMC Vice Chancellor for Research. For more information about the Open Access Fund, please see http://library.kumc.edu/authors-fund.xml. | en_US |
dc.description.abstract | Variation in methotrexate (MTX) efficacy represents a significant barrier to early and effective disease control in the treatment of autoimmune arthritis. We hypothesize that the utilization of metabolomic techniques will allow for an improved understanding of the biochemical basis for the pharmacological activity of MTX, and can promote the identification and evaluation of novel molecular biomarkers of MTX response. In this work, erythroblastoid cells were exposed to MTX at the physiologic concentration of 1,000 nM and analyzed using three metabolomic platforms to give a broad spectrum of cellular metabolites. MTX pharmacological activity, defined as cellular growth inhibition, was associated with an altered cellular metabolomic profile based on the analysis of 724 identified metabolites. By discriminant analysis, MTX treatment was associated with increases in ketoisovaleric acid, fructose, galactose, and 2‐deoxycytidine, and corresponding reductions in 2‐deoxyuridine, phosphatidylinositol 32:0, orotic acid, and inosine monophosphate. Inclusion of data from analysis of folate metabolism in combination with chemometric and metabolic network analysis demonstrated that MTX treatment is associated with dysregulated folate metabolism and nucleotide biosynthesis, which is in line with its known mechanism of action. However, MTX treatment was also associated with alterations in a diversity of metabolites, including intermediates of amino acid, carbohydrate, and lipid metabolism. Collectively, these findings support a robust metabolic response following exposure to physiologic concentrations of MTX. They also identify various metabolic intermediates that are associated with the pharmacological activity of MTX, and are, therefore, potential molecular biomarker candidates in future preclinical and clinical studies of MTX efficacy in autoimmune arthritis. | en_US |
dc.description.sponsorship | University of Kansas and a Clinical and Translational Science Award (CTSA) grant from NCATS awarded to the University of Kansas for Frontiers: University of Kansas Clinical and Translational Science Institute (#KL2TR002367) | en_US |
dc.description.sponsorship | Centers of Biomedical Research Excellence (COBRE) grant awarded by NIGMS (#P20GM130423) | en_US |
dc.description.sponsorship | The University of Kansas (KU) One University Open Access Author Fund sponsored jointly by the KU Provost | en_US |
dc.description.sponsorship | KU Vice Chancellor for Research & Graduate Studies | en_US |
dc.description.sponsorship | KUMC Vice Chancellor for Research and managed jointly by the Libraries at the Medical Center and KU ‐ Lawrence | en_US |
dc.publisher | Wiley Open Access | en_US |
dc.rights | © 2019 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.title | Metabolomic Profiling to Identify Molecular Biomarkers of Cellular Response to Methotrexate In Vitro | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Funk, Ryan S. | |
kusw.kuauthor | Singh, Rakesh K. | |
kusw.kudepartment | Pharmacy Practice | en_US |
dc.identifier.doi | 10.1111/cts.12694 | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.rights.accessrights | openAccess | en_US |
Files in this item
This item appears in the following Collection(s)
-
KU Scholarly Papers Funded by the KU Open Access Fund [212]
-
University of Kansas Medical Center Scholarly Works [77]
KUMC faculty publications from BioMed Central
Except where otherwise noted, this item's license is described as: © 2019 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.